RE:RE:RE:Expectations with tesamorelin in NASH/NAFLD should be highIn the US, doctors are allowed to prescribe a drug for off label use, but pharmas cannot promote off label use and insurance companies are likely to not reimburse it. So how many patients are rich enough to pay totally for Egrifta and will have a doctor willing to prescribe it off label? Not many. In fact, almost nobody. Off label use of Ozempic for obesity is now so important that doctors don't need sales reps to make them aware of it. Even here in Canada Ozempic was prescribed by doctors off label and insurance companies at the beginning were mostly reimbursing it, but now the insurance companies are backtracking. They realized it was costing them too much. Also, here in Quebec we have government insurance program for drugs, and they never reimbursed Ozempic for obesity, only for type 2 diabetes. All that to say that off label use will never be the way for Thera to increase sales of Egrifta. It's a very expensive niche drug that most potential off label users could not pay for.